Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade

The Basis of Oncoimmunology

(2016) A. Karolina Palucka et al.   CELL

A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity

(2016) Yan Luan et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

(2016) Padmanee Sharma et al.   LANCET ONCOLOGY

Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations

(2016) Axel Hoos   NATURE REVIEWS DRUG DISCOVERY

Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy

(2016) Ju Yeon Lee et al.   Nature Communications

PD-L1 Blockade for Cancer Treatment: MEDI4736

(2015) Ramy Ibrahim et al.   SEMINARS IN ONCOLOGY

Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1

(2015) Krzysztof M. Zak et al.   STRUCTURE

Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody

(2015) R. Stewart et al.   Cancer Immunology Research

A generic approach to engineer antibody pH-switches using combinatorial histidine scanning libraries and yeast display

(2014) Christian Schröter et al.   mAbs

A general protocol for the generation of Nanobodies for structural biology

(2014) Els Pardon et al.   Nature Protocols

In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates

(2014) C. Wang et al.   Cancer Immunology Research

Nanobodies: Natural Single-Domain Antibodies

(2013) Serge Muyldermans   Annual Review of Biochemistry

Structure and Interactions of the Human Programmed Cell Death 1 Receptor

(2013) Xiaoxiao Cheng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer

(2013) James D Mellor et al.   Journal of Hematology & Oncology

New checkpoint inhibitors ride the immunotherapy tsunami

(2013) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

Structural and dynamic control of T-cell receptor specificity, cross-reactivity, and binding mechanism

(2012) Brian M. Baker et al.   IMMUNOLOGICAL REVIEWS

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

T cell exhaustion

(2011) E John Wherry   NATURE IMMUNOLOGY

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

(2010) Kaori Sakuishi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions

(2009) O Akbari et al.   Mucosal Immunology

VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin AahI′

(2008) Issam Hmila et al.   MOLECULAR IMMUNOLOGY

The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors

(2008) D. Y.-w. Lin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2

(2008) E. Lazar-Molnar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA